厄洛替尼联合含吉西他滨化疗方案治疗转移性胰腺癌的临床观察  

Clinical Observation of Erlotinib Associated containing Gemcitabine Chemotherapy project Treating Patients with Advanced Pancreatic Cancer

作　　者：戴永美[1,2] 刘振华[1,2] 陈峥[1,2] 张桂枫[1,2] 陈静波[1,2] 郑建萍[1,2] 崔同建[1,2] 

机构地区：[1]福建医科大学省立临床医学院 [2]福建省立医院肿瘤内科

出　　处：《药品评价》2012年第30期14-15,18,共3页Drug Evaluation

摘　　要：目的:观察厄洛替尼联合含吉西他滨化疗方案治疗转移性胰腺癌的疗效、临床获益反应和不良反应。方法:分析11例未接受过全身化疗的转移性胰腺癌患者的临床资料,观察近期疗效、不良反应和临床获益情况。结果:11例患者中无CR、PR病例,7例病情稳定,4例病情进展,疾病控制率为63.6%,临床获益率27.3%。血液学毒性发生率为81.8%(9例),血红蛋白、白细胞、血小板下降均有出现。其中3～4度白细胞下降18.2%(2例)、3～4度中性粒细胞下降发生率为36.4%(4例)、无3～4度血小板下降发生。皮疹发生率为36.4%(4例),均为1～2度皮疹,2例出现1度腹泻,1例出现2度腹泻,4例出现1～2度转氨酶升高。无化疗相关的死亡。结论:厄洛替尼联合含吉西他滨化疗方案治疗转移性胰腺癌,总体临床耐受性好,可以改善患者的生活质量,主要的不良反应是血液学毒性和皮疹。Objective： To evaluate the efficacy,clinical benefits and toxicities of erlotinib associated containing gemcitabine chemotherapy project treating Patients with Advanced Pancreatic Cancer.Method： Clinical data of 11 patients with advanced pancreatic cancer was reviewed retrospectively.All patients treated erlotinib 100～150mg/d plus containing gemcitabine chemotherapy project.Results： No patient achieved complete remission or partial remission,7 patients（63.6%）had stable disease,and 4 patients（36.4%）experienced disease progression,clinical benefit rate was 27.3%.The total incidence of hematologic toxicity was 81.8%,including 18.2% of grade 3～4 leucopenia,36.4% of grade 3～4 neutrophilicgranulocyte.Four patients（36.4%） had rash,which were all grade 1～2.Two patients had grade 1 diar-rhea and one had grade 2.Four patients had grade 1～2 transaminase elevation.No chemotherapy-related death occurred.Conclusions： Gemcitabine combined with erlotinib is an effective regimen for pancreatic cancer with good clinical tolerance.The most common adverse events are hematologic toxicities and rash.

关 键 词：转移性胰腺癌 厄洛替尼 吉西他滨 疗效 不良反应 

分 类 号：R735.9[医药卫生—肿瘤]